$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

$csbr Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000162828022024751 Filed on September 12, 2022

Income Statement

Concept	2022 Q3
Revenue	$13.75M
YoY Change	22.15%
Cost Of Revenue	$7.052M
YoY Change	30.69%
Gross Profit	$6.693M
YoY Change	14.27%
Gross Profit Margin	48.69%
Selling, General & Admin	$4.090M
YoY Change	9.71%
% of Gross Profit	61.11%
Research & Development	$2.887M
YoY Change	25.3%
% of Gross Profit	43.13%
Depreciation & Amortization	$499.0K
YoY Change	57.41%
% of Gross Profit	7.46%
Operating Expenses	$6.977M
YoY Change	15.67%
Operating Profit	-$284.0K
YoY Change	62.29%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$18.00K
YoY Change	-205.88%
Pretax Income	-$302.0K
YoY Change	91.14%
Income Tax	$17.00K
% Of Pretax Income
Net Earnings	-$319.0K
YoY Change	85.47%
Net Earnings / Revenue	-2.32%
Basic Earnings Per Share	-$0.02
Diluted Earnings Per Share	-$0.02
COMMON SHARES
Basic Shares Outstanding	13.52M shares
Diluted Shares Outstanding	13.52M shares

Balance Sheet

Concept	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.058M
YoY Change	101.55%
Cash & Equivalents	$8.100M
Short-Term Investments
Other Short-Term Assets	$958.0K
YoY Change	10.88%
Inventory
Prepaid Expenses
Receivables	$9.355M
Other Receivables	$0.00
Total Short-Term Assets	$18.37M
YoY Change	45.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.698M
YoY Change	13.83%
Goodwill	$335.0K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$15.00K
YoY Change	-82.56%
Total Long-Term Assets	$16.02M
YoY Change	3.26%
TOTAL ASSETS
Total Short-Term Assets	$18.37M
Total Long-Term Assets	$16.02M
Total Assets	$34.39M
YoY Change	22.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.537M
YoY Change	-24.16%
Accrued Expenses	$1.957M
YoY Change	-1.21%
Deferred Revenue	$10.89M
YoY Change	98.6%
Short-Term Debt	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$16.62M
YoY Change	42.34%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00
YoY Change
Other Long-Term Liabilities	$660.0K
YoY Change	172.73%
Total Long-Term Liabilities	$660.0K
YoY Change	172.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.62M
Total Long-Term Liabilities	$660.0K
Total Liabilities	$25.41M
YoY Change	23.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$72.30M
YoY Change	-0.55%
Common Stock	$81.28M
YoY Change	1.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.983M
YoY Change
Total Liabilities & Shareholders Equity	$34.39M
YoY Change	22.35%

Cashflow Statement

Concept	2022 Q3
OPERATING ACTIVITIES
Net Income	-$319.0K
YoY Change	85.47%
Depreciation, Depletion And Amortization	$499.0K
YoY Change	57.41%
Cash From Operating Activities	-$195.0K
YoY Change	-190.28%
INVESTING ACTIVITIES
Capital Expenditures	$754.0K
YoY Change	-16.87%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$754.0K
YoY Change	-16.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00
YoY Change	-100.0%
NET CHANGE
Cash From Operating Activities	-$195.0K
Cash From Investing Activities	-$754.0K
Cash From Financing Activities	$0.00
Net Change In Cash	-$949.0K
YoY Change	37.74%
FREE CASH FLOW
Cash From Operating Activities	-$195.0K
Capital Expenditures	$754.0K
Free Cash Flow	-$949.0K
YoY Change	37.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	dei	Amendment Flag AmendmentFlag	false
CY2022Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q3	dei	Entity Central Index Key EntityCentralIndexKey	0000771856
CY2022Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2022Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ServiceMember
CY2021Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ServiceMember
CY2022Q3	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ServiceMember
CY2021Q3	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ServiceMember
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet
CY2022Q3	dei	Document Type DocumentType	10-Q
CY2022Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q3	dei	Document Period End Date DocumentPeriodEndDate	2022-07-31
CY2022Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q3	dei	Entity File Number EntityFileNumber	001-11504
CY2022Q3	dei	Entity Registrant Name EntityRegistrantName	CHAMPIONS ONCOLOGY, INC.
CY2022Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-1401755
CY2022Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	One University Plaza, Suite 307
CY2022Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07601
CY2022Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Hackensack
CY2022Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022Q3	dei	City Area Code CityAreaCode	201
CY2022Q3	dei	Local Phone Number LocalPhoneNumber	808-8400
CY2022Q3	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022Q3	dei	Trading Symbol TradingSymbol	CSBR
CY2022Q3	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q3	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13522441	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8058000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9007000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9355000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9513000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	958000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1144000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	18371000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	19664000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7971000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8230000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7698000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7134000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	335000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	335000	usd
CY2022Q3	us-gaap	Assets Assets	34390000	usd
CY2022Q2	us-gaap	Assets Assets	35378000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2537000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2868000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1957000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2414000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1099000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1054000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	142000	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	72000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10885000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11071000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	16620000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	17479000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8127000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8412000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	660000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	391000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	25407000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	26282000	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13522441	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13522441	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13522441	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13522441	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	14000	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	14000	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	81270000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	81064000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72301000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71982000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8983000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9096000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34390000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35378000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13745000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11253000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7052000	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5396000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2887000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2304000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1692000	usd
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1574000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2398000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2154000	usd
CY2022Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	14029000	usd
CY2021Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	11428000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-284000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-175000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-18000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-302000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-158000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-319000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-172000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13522433	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13401929	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13522433	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13401929	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9096000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	206000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-319000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8983000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	7428000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	280000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-172000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	7538000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-319000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-172000	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	206000	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	280000	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	528000	usd
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	317000	usd
CY2022Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2021Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	4000	usd
CY2022Q3	csbr	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	269000	usd
CY2021Q3	csbr	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	245000	usd
CY2022Q3	csbr	Reversal Of Provision For Doubtful Accounts ReversalOfProvisionForDoubtfulAccounts	0	usd
CY2021Q3	csbr	Reversal Of Provision For Doubtful Accounts ReversalOfProvisionForDoubtfulAccounts	78000	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-158000	usd
CY2021Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	825000	usd
CY2022Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-186000	usd
CY2021Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-93000	usd
CY2022Q3	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
CY2021Q3	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	70000	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-331000	usd
CY2021Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1372000	usd
CY2022Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-456000	usd
CY2021Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-250000	usd
CY2022Q3	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	usd
CY2021Q3	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	15000	usd
CY2022Q3	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
CY2021Q3	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	62000	usd
CY2022Q3	csbr	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	250000	usd
CY2021Q3	csbr	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	150000	usd
CY2022Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-186000	usd
CY2021Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-775000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-195000	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	216000	usd
CY2022Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	754000	usd
CY2021Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	907000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-754000	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-907000	usd
CY2022Q3	csbr	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	0	usd
CY2021Q3	csbr	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	2000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-949000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-689000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9007000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4687000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8058000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3998000	usd
CY2022Q3	csbr	Number Of Operating Subsidiaries NumberOfOperatingSubsidiaries	3	subsidiary
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-319000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-195000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72300000	usd
CY2022Q3	csbr	Working Capital Deficit WorkingCapitalDeficit	1800000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8100000	usd
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1722155	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1734428	shares
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	usd
CY2021Q3	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2022Q3	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2022Q3	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	0	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	11071000	usd
CY2022Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	5619000	usd
CY2022Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	6037000	usd
CY2022Q3	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	4366000	usd
CY2022Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	4106000	usd
CY2022Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	9985000	usd
CY2022Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	10143000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	630000	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	630000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9355000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9513000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	10885000	usd
CY2022Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	528000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13745000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11253000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13803000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12711000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6105000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5577000	usd
CY2022Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7698000	usd
CY2022Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7134000	usd
CY2021Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	317000	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	499000	usd
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	317000	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	1081000	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	713000	usd
CY2022Q3	csbr	Finance Lease Depreciation And Amortization Expenses FinanceLeaseDepreciationAndAmortizationExpenses	29000	usd
CY2021Q3	csbr	Finance Lease Depreciation And Amortization Expenses FinanceLeaseDepreciationAndAmortizationExpenses	0	usd
CY2022Q1	us-gaap	Servicing Asset ServicingAsset	1900000	usd
CY2022Q3	us-gaap	Servicing Asset At Amortized Value ServicingAssetAtAmortizedValue	1300000	usd
CY2022Q3	us-gaap	Hosting Arrangement Service Contract Implementation Cost Expense Amortization HostingArrangementServiceContractImplementationCostExpenseAmortization	157000	usd
CY2021Q3	us-gaap	Hosting Arrangement Service Contract Implementation Cost Expense Amortization HostingArrangementServiceContractImplementationCostExpenseAmortization	40000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	206000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	280000	usd
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0287
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0082
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.6258
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.6594
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6621
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.50
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.33
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1658239	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.51
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M24D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6131000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	78000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.57
CY2022Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y10M24D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	7625	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.73
CY2022Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	1875	shares
CY2022Q3	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	4.63
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	4584	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5.40
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1722155	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.64
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M24D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7462000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1722155	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.64
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y10M24D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	7462000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1380775	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.06
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y1M6D
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6846000	usd
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	467000	usd
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	452000	usd
CY2020Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P6M
CY2020Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P6M
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7971000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8230000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1099000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1054000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8127000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8412000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y5M1D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0573
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2060000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2811000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2850000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2896000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2860000	usd
CY2022Q3	csbr	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	5164000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	18641000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9415000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	9226000	usd
CY2022Q3	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	0	usd
CY2022Q3	us-gaap	Royalty Expense RoyaltyExpense	76000	usd
CY2021Q3	us-gaap	Royalty Expense RoyaltyExpense	44000	usd

Files In Submission

Name	View Source	Status
0001628280-22-024751-index-headers.html	Edgar Link	pending
0001628280-22-024751-index.html	Edgar Link	pending
0001628280-22-024751.txt	Edgar Link	pending
0001628280-22-024751-xbrl.zip	Edgar Link	pending
csbr-20220731.htm	Edgar Link	pending
csbr-20220731.xsd	Edgar Link	pending
csbrq1731202210-qex311.htm	Edgar Link	pending
csbrq1731202210-qex312.htm	Edgar Link	pending
csbrq1731202210-qex321.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
csbr-20220731_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
csbr-20220731_pre.xml	Edgar Link	unprocessable
csbr-20220731_lab.xml	Edgar Link	unprocessable
csbr-20220731_htm.xml	Edgar Link	completed
csbr-20220731_def.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

2022 Q3 Form 10-Q Financial Statement

#000162828022024751 Filed on September 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR CHAMPIONS ONCOLOGY, INC. Stock $csbr

2022 Q3 Form 10-Q Financial Statement

#000162828022024751 Filed on September 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr